S&P 500

S&P 500 Mildly Lower As Gilead Sciences Announces Phase 3 Results

S&P 500 remains unmoved by recent disclosures from Gilead Sciences on its Phase 3 clinical trials of coronavirus treatment candidate Remdesivir.

Continue reading with a free membership account. It takes seconds to create.


Register

Related Posts: